Is enhanced cholesterol synthesis in APOE4 carriers compensatory or directly pathological?

The debate highlighted conflicting interpretations of elevated cholesterol synthesis in APOE4 brains - protective compensation versus harmful dysregulation. Resolving this determines whether cholesterol synthesis should be enhanced or inhibited therapeutically.

Source: Debate session sess_SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e_20260416-135601 (Analysis: SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e)

Resolved when an evidence artifact resolves whether enhanced cholesterol synthesis in APOE4 carriers is compensatory or directly pathological, with one of: (1) APOE4-targeted intervention study (APOE4 ASO, CRISPRi, or small molecule APOE4 expression modulator) in APOE4 KI mice or human iPSC-derived neurons, measuring cholesterol synthesis flux (D2O labeling + LC-MS/MS of newly synthesized cholesterol), neuronal viability, and synapse density, determining whether reducing cholesterol synthesis rescues neurodegeneration phenotypes (>=30% improvement in >=2 readouts) or worsens them; (2) Mendelian randomization using human genetic data (AD GWAS, brain exprQTL) testing whether variants in cholesterol synthesis genes (HMGCR, FDFT1, CYP51A1) that increase cholesterol synthesis are associated with increased or decreased AD risk, with n >= 50,000 AD cases and controls; (3) APOE4 KI mice with neuron-specific cholesterol synthesis radioisotope tracing, demonstrating whether enhanced cholesterol synthesis is localized to neurons versus glia and whether it accumulates in membrane lipid rafts associated with amyloid or tau pathology.